Vave 10 mg Tablets: Each coated tablet contains Domperidone 10 mg as Maleate BP.
Vave ODT 10 mg: Each orodispersible tablet contains Domperidone BP 10 mg.
Vave Suspension: Each 5 ml contains Domperidone BP 5 mg.
Vave Paediatric Drops: Each ml contains Domperidone BP 5 mg.
Vave ® is a dopamine antagonist that principally blocks the dopamine receptors located in the chemoreceptor trigger zone (CTZ) and stomach. Its gastro-prokinetic action is based on its blocking effect of dopamine receptors that have an influence on the motility of gastro-intestinal tract. Due to its weak penetration across the blood-brain barrier, Vave® has almost no effect on the dopaminergic receptors in the brain therefore excluding psychotropic and neurologic side effects. Vave® restores normal motility and tone of the upper gastro-intestinal tract, facilitates gastric emptying, enhances antral and duodenal peristalsis and regulates contraction of the pylorus. Vave® also increases esophageal peristalsis and lower esophageal sphincter pressure, and thus prevents regurgitation of gastric content.
Dose and frequency of administration should be adjusted according to severity and duration of symptoms. Vave® tablet, ODT, suspension and paediatric drops should be taken 15-30 minutes before meal.
For the treatment of nausea and vomiting: Adults: 10-20 mg (1-2 Vave® tablet/ Vave® ODT or 10-20 ml suspension), every 4-8 hours daily. Children: 0.2-0.4 mg/kg (0.2-0.4 ml suspension/kg or 0.04-0.08 ml paediatric drops/kg) body weight, every 4-8 hours daily. A course of treatment should not exceed 12 weeks.
For the treatment of symptoms of functional dyspepsia: Adults: 10-20 mg (1-2 Vave® tablet/ Vave® ODT or 10-20 ml suspension), every 4-8 hours daily. Children: 0.2-0.4 mg/kg (0.2-0.4 ml suspension/kg or 0.04-0.08 ml paediatric drops/kg) body weight, every 4-8 hours daily.
Potent CYP3A4 inhibitors (ketoconazole, erythromycin) and QT-prolonging agents increase ventricular arrhythmia risk (avoid combination); anticholinergic drugs antagonize prokinetic effects; antacids reduce bioavailability.
Domperidone is contraindicated to the patients with known hypersensitivity to this drug and in case of neonates.
Common: Hyperprolactinemia (galactorrhea, breast enlargement, reduced libido), dry mouth, headache. Less Common: Diarrhea, skin rash, pruritus, nervousness, drowsiness. Rare: Extrapyramidal reactions (0.05%).
Overdose
No case of overdosage with oral dompoeridone has been reported. There is no specific antidote to Domperidone but in the event of overdosage gastric lavage may be useful.
Category C. Safe use in pregnancy not established; not recommended during pregnancy unless essential. Lactation: Secreted in breast milk in very small quantities; use under physician supervision.
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.